SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Resmed disclosed quarterly and fiscal year 2026 financial results for the period ended June 30, 2026, reporting revenue growth of 9% to $1.5 billion in Q4 and 10% to $5.7 billion for FY2026, with detailed financial statements and EPS metrics included in the earnings announcement.
View raw filing on EDGAR →This is a clear earnings release disclosing Hyperfine's second quarter 2026 financial results. The Item 2.02 filing announces Q2 2026 revenues of $3.9 million (up 44.8% YoY), gross profit of $2.0 million with 50.7% gross margin, and a net loss of $9.3 million ($0.09 per share). The press release also provides full-year 2026 guidance and business highlights including CE Marking approval and European launch. The disclosure includes condensed consolidated financial statements (balance sheet, income statement, and cash flow statement) and is material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →This is a standard earnings release disclosing Q2 2026 financial results for Evommune, Inc., filed under Item 2.02 (Results of Operations and Financial Condition). The press release includes unaudited condensed consolidated statements of operations and balance sheets, showing net loss of $32.2 million and $53.9 million for Q2 and H1 2026 respectively, along with cash position of $288.0 million as of June 30, 2026. The disclosure is material to investors assessing the company's financial condition and cash runway through 2028.
View raw filing on EDGAR →Fidus Investment Corporation issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, including total investment income of $43.5 million, net investment income of $18.7 million ($0.49 per share), and NAV of $738.5 million ($19.46 per share).
View raw filing on EDGAR →This is a straightforward earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R&D expenses ($15.2M vs $9.4M YoY), G&A expenses ($5.4M vs $4.3M YoY), net loss ($17.8M vs $12.3M YoY), and cash position ($318.9M). The filing also includes selected balance sheet and statement of operations data, which are typical components of an earnings announcement.
View raw filing on EDGAR →This is a standard earnings release disclosing quarterly and six-month financial results for the period ended June 30, 2026. The press release reports key financial metrics including cash position ($970.9 million), R&D expenses ($31.0 million for Q2), G&A expenses ($11.0 million for Q2), and net loss ($22.0 million for Q2), along with condensed balance sheets and statements of operations. The disclosure is material to investors assessing the company's financial condition and cash runway as a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →ARKO Petroleum Corp. disclosed financial results for Q2 2026 and the six-month period ended June 30, 2026, reporting net income of $12.2 million and Adjusted EBITDA of $39.8 million, with reaffirmed full-year strategic guidance.
View raw filing on EDGAR →ARKO Petroleum disclosed Q2 2026 financial results ended June 30, 2026, reporting net income of $12.2 million and Adjusted EBITDA of $39.8 million, with reaffirmed full-year 2026 guidance.
View raw filing on EDGAR →ICF International announced its financial results for the second quarter ended June 30, 2026, including quarterly revenue of $474.5 million, net income of $26.9 million, and diluted EPS of $1.49, with reaffirmed full-year 2026 guidance ranges for revenue, GAAP EPS, and Non-GAAP EPS.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses quarterly financial results including R&D expenses ($21.9M), G&A expenses ($5.0M), net loss ($25.0M), and cash position ($349.4M), along with condensed balance sheets and statements of operations. The disclosure is material to investors as it provides the registrant's financial performance and runway guidance (expected to fund operations into 2029).
View raw filing on EDGAR →This is a clear earnings release for Onto Innovation's fiscal second quarter ended June 30, 2026, filed on August 6, 2026. The Item 2.02 disclosure announces quarterly financial results including record revenue of $343 million (up 18% sequentially and 35.3% year-over-year), gross margin of 53.4%, operating income of $63.6 million, and diluted EPS of $1.21. The company also provided forward guidance for Q3 2026. The earnings release is attached as Exhibit 99.1 and contains detailed financial highlights, operating results, and management commentary on business momentum.
View raw filing on EDGAR →JFrog issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing total revenues of $163.8 million (up 29% YoY), cloud revenues of $87.5 million (up 53% YoY), and providing forward guidance for Q3 and full-year 2026. This is a standard quarterly earnings release with comprehensive financial metrics and operational highlights, clearly falling under Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →CleanSpark disclosed financial results for its fiscal quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly revenues ($138.0 million), net loss ($239.8 million or $0.89 per share), and Adjusted EBITDA ($113.0 million loss), along with balance sheet highlights and forward-looking guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and operational trajectory.
View raw filing on EDGAR →This is a quarterly earnings release for Q2 2026 disclosing financial results (net loss of $22.3 million, R&D expenses of $18.0 million, G&A expenses of $6.2 million, and cash position of $227.1 million) along with business highlights and clinical trial updates. The filing explicitly states it is furnished under Item 2.02 of Form 8-K and includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 6, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated balance sheets and statements of operations. The filing includes detailed financial metrics (R&D expenses of $48.7M, G&A expenses of $26.4M, net loss of $159.0M) and material clinical program updates (positive Phase 3 Emerge results for DT120 ODT in MDD, cash position of $1.1 billion). This is material to investors as it discloses quarterly financial performance and significant clinical milestones for a late-stage biopharmaceutical company.
View raw filing on EDGAR →Alector disclosed its second quarter 2026 financial results on August 6, 2026, via a press release (Exhibit 99.1) attached to the 8-K Item 2.02. The disclosure includes consolidated statements of operations showing collaboration revenue of $3.3 million, operating expenses of $27.7 million, and a net loss of $22.9 million ($0.21 per share) for Q2 2026, along with balance sheet data and cash position of $172.8 million. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational performance.
View raw filing on EDGAR →CytomX issued a press release on August 6, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026, including condensed balance sheets and statements of operations. The disclosure includes Q2 2026 revenue ($1.4M), operating expenses ($25.2M), cash position ($330.3M), and cash runway projections, along with pipeline program updates and corporate developments. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →AVITA Medical issued a press release on August 6, 2026, announcing Q2 2026 financial results, including record revenue of $21.7 million (18% YoY growth), improved gross margins, and raised full-year 2026 revenue guidance to $86–$89 million. The disclosure includes consolidated financial statements and forward guidance, which are hallmarks of an earnings release under Item 2.02. The company also announced expectations to reach cash flow breakeven in Q4 2026, a material milestone for investor assessment.
View raw filing on EDGAR →Relay Therapeutics announced second quarter 2026 financial results on August 6, 2026, reporting revenue of $0.4 million, R&D expenses of $76.5 million, G&A expenses of $14.7 million, a net loss of $83.7 million ($0.41 per share), and a cash position of $911 million, along with clinical progress updates.
View raw filing on EDGAR →CarGurus announced Q2 2026 financial results on August 6, 2026, reporting revenue of $251.0 million (13% YoY growth), GAAP net income of $49.2 million, and adjusted EBITDA of $84.7 million, along with forward guidance for Q3 and full-year 2026.
View raw filing on EDGAR →Xenon Pharmaceuticals reported Q2 2026 financial results for the three and six months ended June 30, 2026, disclosing a net loss of $110.7M, R&D expenses of $99.2M, G&A expenses of $23.9M, other income of $11.8M, and a cash position of $1.245B, along with clinical development updates on its pipeline programs including azetukalner.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The Item 2.02 disclosure explicitly states that Lineage "issued a press release announcing financial results for the quarter ended June 30, 2026," with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenues ($1.1M), operating expenses ($10.0M), operating loss ($8.9M), and net income ($1.5M), along with balance sheet highlights and comprehensive business updates on clinical programs and pipeline progress.
View raw filing on EDGAR →This is a clear earnings release disclosing Cytokinetics' Q2 2026 financial results, including total revenues of $28.6 million (with $25.3 million from MYQORZO product sales), R&D expenses of $97.8 million, SG&A expenses of $104.4 million, and a net loss of $198.8 million. The press release is furnished as Exhibit 99.1 and includes detailed financial metrics, cash position ($1.7 billion), and updated 2026 guidance, which are material to investors assessing the company's financial performance and runway.
View raw filing on EDGAR →This is a clear earnings release disclosing Organogenesis's Q2 2026 financial results via press release furnished as Exhibit 99.1. The filing reports net revenue of $42.8 million (down 58% YoY), net loss of $96.3 million (vs. $9.4 million loss in Q2 2025), and significantly reduced full-year 2026 guidance (62-68% revenue decline). The material deterioration in financial performance—including a $86.9 million increase in net loss and substantial revenue contraction—would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →Guardian Pharmacy Services issued a press release on August 6, 2026 reporting Q2 2026 financial results for the quarter ended June 30, 2026, including revenue of $351.8 million, net income of $22.1 million, and adjusted EBITDA of $29.7 million. The company also raised its full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1, which is the archetypal earnings_release event.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure states that Navient "issued an informational press release announcing its financial results for the quarter ended June 30, 2026" and posted complete financial results to its website. The attached exhibits (EX-99.1 and EX-99.2) contain the formal earnings announcement with GAAP net income of $25 million ($0.26 diluted EPS), Core Earnings of $27 million ($0.29 diluted EPS), segment results, and detailed financial metrics. This is a material quarterly earnings disclosure typical of Item 2.02 filings.
View raw filing on EDGAR →TechTarget issued a press release on August 6, 2026 announcing financial results for Q2 and H1 2026, disclosing revenues of $116.1 million (Q2) and $222.2 million (H1), net losses, Adjusted EBITDA metrics, and reiterated 2026 growth guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, meeting the definition of earnings_release.
View raw filing on EDGAR →QuinStreet issued a press release on August 6, 2026 announcing financial results for the fourth quarter and full fiscal year ended June 30, 2026. The disclosure includes record quarterly and annual revenue ($373.9M and $1.3B respectively), record net income ($19.1M and $81.2M), and record adjusted EBITDA ($41.4M and $112.5M), along with forward guidance for Q1 and FY2027. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →Turtle Beach Corporation issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, including net revenue of $56.4 million, net loss of $7.3 million, and adjusted EBITDA of $1.3 million. The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes quarterly financial statements and full-year 2026 guidance reaffirmation.
View raw filing on EDGAR →Oculis Holding AG reported Q2 2026 financial results, including condensed consolidated financial statements showing a cash position of $282.3 million and detailed operating expenses. The earnings announcement includes balance sheet and income statement data typical of a quarterly financial results disclosure.
View raw filing on EDGAR →TerrAscend issued a press release on August 6, 2026 announcing Q2 2026 financial results, disclosing net revenue of $67.1 million, gross profit margin of 54.0%, Adjusted EBITDA of $17.7 million, and 16 consecutive quarters of positive operating cash flow.
View raw filing on EDGAR →Alta Equipment Group Inc. issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2026, including detailed financial statements, segment performance metrics, CEO commentary, and full-year 2026 guidance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release announces financial results including revenue ($5.0M collaboration/license revenue), operating expenses (R&D $8.5M, G&A $6.9M), and net income ($50.2M, driven largely by non-cash gains on fair value changes). The filing includes unaudited condensed consolidated statements of operations and comprehensive loss, which are standard components of an earnings disclosure. Material to investors as it provides quarterly financial performance and updates on clinical development milestones.
View raw filing on EDGAR →American Healthcare REIT issued an earnings release on August 6, 2026, announcing second quarter 2026 financial results including GAAP net income of $0.16 per diluted share, NFFO of $0.54 per diluted share, and 13.2% portfolio Same-Store NOI growth. The company also raised full-year 2026 guidance for NFFO per diluted share to $2.15–$2.19 and Same-Store NOI growth to 11.0%–13.0%.
View raw filing on EDGAR →This is a clear earnings release disclosing Phunware's financial results for Q2 2026 and the first six months of 2026. The press release (Exhibit 99.1) reports net revenue of $0.8 million (up 76% YoY), gross margin of 69%, net loss of $5.2 million, and cash position of $92.1 million with no debt. The filing is made under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases, and the company explicitly states the press release is "furnished herewith as Exhibit 99.1."
View raw filing on EDGAR →This is a straightforward earnings release disclosing financial results for the three and six months ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents consolidated statements of operations and balance sheets, net loss figures ($3.3M and $6.3M respectively), cash position ($11.5M), and operational highlights including clinical trial progress. The disclosure is material to investors assessing the company's financial condition and runway.
View raw filing on EDGAR →Exzeo Group issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing key metrics including revenue of $57.8 million, net income of $23.3 million, and earnings per share of $0.26. The earnings release is furnished as Exhibit 99.1 to the 8-K filing under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →MBIA issued a press release on August 6, 2026 announcing quarterly financial results for the period ended June 30, 2026, with the financial results report attached as Exhibit 99.1.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure states that "Drilling Tools International Corporation (the 'Company') issued a press release announcing the Company's financial and operating results for the second quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, revenue breakdowns ($38.1M total revenue), net loss ($1.8M), EPS ($0.05 loss per share), and full-year 2026 guidance reaffirmed by management. This is a material quarterly earnings announcement typical of Item 2.02 disclosures.
View raw filing on EDGAR →HCI Group disclosed its quarterly and six-month financial results for the period ended June 30, 2026, including pre-tax income of $111 million and $226 million respectively, diluted EPS of $5.60 and $11.05, and detailed revenue and expense breakdowns. The Item 2.02 disclosure explicitly states "we released our earnings for the three and six months ended June 30, 2026" and references the earnings release as Exhibit 99.1, which is a standard earnings release format with management commentary, financial statements, and conference call details.
View raw filing on EDGAR →NETGEAR issued a press release on August 6, 2026 announcing its financial results for the second fiscal quarter ended June 28, 2026, disclosing Q2 2026 net revenue of $168.6 million, GAAP operating loss of $(8.4) million, and non-GAAP operating income of $4.0 million, along with segment performance and forward guidance for Q3 2026.
View raw filing on EDGAR →indie Semiconductor issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $64.0 million (up 24% Y-o-Y), GAAP operating loss of $35.1 million, and Non-GAAP operating loss of $8.9 million, along with Q3 2026 revenue guidance of $67–$73 million.
View raw filing on EDGAR →Mercer International Inc. announced its second quarter 2026 financial results via press release on August 6, 2026, disclosing operating EBITDA of negative $21.0 million, net loss of $76.0 million, and detailed segment performance. This is a standard quarterly earnings release filed under Item 2.02 with the press release furnished as Exhibit 99.1, meeting the definition of earnings_release.
View raw filing on EDGAR →This is a standard earnings release disclosing Verrica's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenue of $5.9 million in Q2 2026, U.S. YCANTH net product revenue of $5.1 million, and a net loss of $13.2 million for the quarter. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →This is a clear earnings release disclosing Bright Mountain Media's financial results for Q2 2026 and the six-month period ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents consolidated statements of operations, balance sheets, and detailed revenue/expense breakdowns. The company reports a net loss of $3.2 million for Q2 2026 (improved 22% from prior year) and $4.5 million for the six-month period (improved 38% from prior year), along with adjusted EBITDA metrics. This is a material disclosure affecting investor assessment of the registrant's financial performance and operational results.
View raw filing on EDGAR →Morgan Stanley Direct Lending Fund issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net investment income of $0.45 per share, net asset value of $19.50 per share, and declaring a regular dividend of $0.45 per share.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, disclosed via Item 2.02 and furnished as Exhibit 99.1. The press release announces financial results including revenue of $66.0 million (down 13%), net loss of $4.8 million, and revised full-year 2026 guidance showing material declines in revenue (down 19% at midpoint) and Adjusted EBITDA (down 16% at midpoint). The disclosure is material as it reflects significant deterioration in financial performance and reduced forward guidance.
View raw filing on EDGAR →This is a standard earnings release disclosing Arcturus' financial results for Q2 2026 (quarter ended June 30, 2026), including revenue, R&D expenses, net loss, and balance sheet metrics. The press release (Exhibit 99.1) announces quarterly financial results and provides corporate updates on pipeline progress. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.
View raw filing on EDGAR →The company disclosed quarterly financial results for Q2 2026 ended June 30, 2026, including net sales, gross margin, operating income, net income, and EPS metrics, along with revised full-year 2026 guidance for adjusted EPS.
View raw filing on EDGAR →Blackstone Secured Lending Fund issued a press release on August 6, 2026, announcing its second quarter 2026 financial results, including net investment income of $174 million ($0.75 per share), net asset value of $25.53 per share, and a declared dividend of $0.77 per share. The detailed presentation is furnished as Exhibit 99.1 and discloses comprehensive quarterly operating results, portfolio activity, and balance sheet metrics—the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →